Back to Search
SEAN HISCOX, PH.D.
PH.D.
Clinical Psychologist
NPI: 1609910975Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
3963(NJ)
Research & Publications (20)
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
PMID 18493848·Breast Cancer Res Treat·2009
8-other
ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
PMID 18583420·Endocrinology·2008
8-other
SRC as a therapeutic target in breast cancer.
PMID 19075780·Endocr Metab Immune Disord Drug Targets·2008
6-review
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
PMID 19055788·Breast Cancer Res·2008
8-other
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
PMID 17686159·Breast Cancer Res·2007
8-other
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.
PMID 17486454·Rev Endocr Metab Disord·2007
6-review
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
PMID 17394086·Clin Exp Metastasis·2007
8-other
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
PMID 16333527·Breast Cancer Res Treat·2006
8-other
Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications.
PMID 17259561·Endocr Relat Cancer·2006
6-review
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer.
PMID 17259559·Endocr Relat Cancer·2006
6-review
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
PMID 17158755·Endocr Relat Cancer·2006
8-other
Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.
PMID 16080193·Int J Cancer·2006
8-other
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
PMID 15860268·J Steroid Biochem Mol Biol·2005
6-review
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
PMID 16113097·Endocr Relat Cancer·2005
6-review
Zinc transporter LIV-1: a link between cellular development and cancer progression.
PMID 15541644·Trends Endocrinol Metab·2004
7-preclinical
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
PMID 15387370·Clin Exp Metastasis·2004
8-other
Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.
PMID 14734490·Clin Cancer Res·2004
8-other
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
PMID 15613453·Endocr Relat Cancer·2004
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 25 N DOUGHTY AVE
SOMERVILLE, NJ 08876 - Phone
- (980) 526-1177
Quick Facts
- NPI
- 1609910975
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile